Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary Prevention

NCT07581808 is registered in ClinicalTrials.gov with University Medical Centre Ljubljana as lead sponsor.

NCT NCT07581808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07581808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary Prevention
Lead sponsor
University Medical Centre Ljubljana
Phase
Phase 4
Overall status
Recruiting
Start date
May 18, 2026
Completion date
June 30, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease (ascvd), hypercholesterolemia